ASX Health Stocks: Genetic Signatures jumps 20pc on FDA update, Proteomics reveals new patent in Japan stockhead.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stockhead.com.au Daily Mail and Mail on Sunday newspapers.
Genetic Signatures: From $4.9m to $28m in annual revenues in just 3 years 6pr.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 6pr.com.au Daily Mail and Mail on Sunday newspapers.
Why the Genetic Signatures (ASX:GSS) share price is edging higher
Aaron Teboneras | January 27, 2021 2:36pm |
More on:
The
Genetic Signatures Ltd(ASX: GSS) share price is edging higher today. This comes after the company announced that it received CE-IVD registration for its 3base EasyScreen sexually transmitted infection (STI) Genital Pathogen Detection Kit.
CE-IVD refers to an approved CE Marking from the European Union for an in vitro diagnostic (IVD) device. This allows the product to be commercially sold within Europe.
What’s driving the Genetic Signatures share price higher
The Genetic Signatures share price is back positive territory as investors jump on the company’s latest news. Originally, the company’s shares were sliding lower on the back of overall weak market sentiment.